GAITHERSBURG, Md.--(BUSINESS WIRE)--April 27, 2006--GenVec, Inc. (Nasdaq:GNVC - News) has been awarded a $500,000 contract to continue the company's malaria vaccine research and development work with the Naval Medical Research Center for a third year. The funds will be used to support GenVec's evaluation of alternative serotype adenovector-based malaria vaccines under the U.S. Navy's congressionally sponsored Agile Vaccine Program.
